Postoperative radiation therapy following the incomplete resection of a non-small cell lung cancer

被引：12

作者：

Park, Jaehyeon ^{[1
]}

Song, Si Yeol ^{[1
]}

Kim, Su Ssan ^{[1
]}

Kim, Sang-We ^{[2
]}

Kim, Woo Sung ^{[2
]}

Park, Seung-Il ^{[3
]}

Kim, Dong Kwan ^{[3
]}

Kim, Yong-Hee ^{[3
]}

Park, Jongmoo ^{[1
]}

Lee, Sang-Wook ^{[1
]}

Kim, Jong Hoon ^{[1
]}

Do Ahn, Seung ^{[1
]}

Choi, Eun Kyung ^{[1
]}

机构：

[1] Univ Ulsan, Coll Med, Dept Radiat Oncol, Seoul, South Korea

[2] Univ Ulsan, Coll Med, Dept Internal Med, Seoul, South Korea

[3] Univ Ulsan, Asan Med Ctr, Coll Med, Dept Cardiovasc & Thorac Surg, Seoul, South Korea

来源：

RADIATION ONCOLOGY JOURNAL | 2014年 / 32卷 / 02期

基金：

新加坡国家研究基金会;

关键词：

Non-small-cell lung carcinoma; R1; resection; Microscopic residual disease; Postoperative radiotherapy;

D O I：

10.3857/roj.2014.32.2.70

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Purpose: To review the results of postoperative radiation therapy (PORT) for residual non-small cell lung cancer (NSCLC) following surgical resection and evaluate multiple clinicopathologic prognostic factors. Materials and Methods: A total of 58 patients, who completed scheduled PORT for positive resection margin, among 658 patients treated with PORT from January 2001 to November 2011 were retrospectively analyzed. Radiation therapy was started at 4 to 6 weeks after surgery. Chemotherapy was also administered to 35 patients, either sequentially or concurrently with PORT. Results: The median age of patients was 63 years (range, 40 to 82 years). The postoperative pathological stage I NSCLC was diagnosed in 10 (17.2%), stage II in 18 (31.0%), and stage III in 30 patients (51.7%). Squamous cell carcinoma was identified in 43, adenocarcinoma in 10, large cell in 1, others in 4 patients. Microscopic residual disease (R1) was diagnosed in 55 patients (94.8%), and the remaining three patients were diagnosed with gross residual disease (R2). The median dose of PORT was 59.4 Gy (range, 50.0 to 64.8 Gy). Chemotherapy was administered to 35 patients (60%), and the median follow-up time was 22.0 months (range, 6.0 to 84.0 months). The 3-year locoregional relapse-free survival and distant metastasis-free survival rates were 82.1% and 52.9%, respectively. The median overall survival was 23.8 months (range, 6.0 to 84.1 months), and the 3-year overall survival rate was 58.2%. Chemotherapy did not influence the failure pattern or survival outcome. Conclusion: PORT is an effective modality for improving local tumor control in incompletely resected NSCLC patients. Major failure pattern was distant metastasis despite chemotherapy.

引用

页码：70 / 76

页数：7

共 10 条

[1]

Kayser K., Anyanwu E., Bauer H.G., Vogt-Moykopf I., Tumor presence at resection boundaries and lymph-node metastasis in bronchial carcinoma patients, Thorac Cardiovasc Surg, 41, pp. 308-311, (1993)

[2]

Ohguri T., Yahara K., Moon S.D., Et al., Postoperative radiotherapy for incompletely resected non-small cell lung cancer: Clinical outcomes and prognostic value of the histological subtype, J Radiat Res, 53, pp. 319-325, (2012)

[3]

Riquet M., Achour K., Foucault C., Le Pimpec Barthes F., Dujon A., Cazes A., Microscopic residual disease after resection for lung cancer: A multifaceted but poor factor of prognosis, Ann Thorac Surg, 89, pp. 870-875, (2010)

[4]

Collaud S., Bongiovanni M., Pache J.C., Fioretta G., Robert J.H., Survival according to the site of bronchial microscopic residual disease after lung resection for non-small cell lung cancer, J Thorac Cardiovasc Surg, 137, pp. 622-626, (2009)

[5]

Karakoyun-Celik O., Yalman D., Bolukbasi Y., Cakan A., Cok G., Ozkok S., Postoperative radiotherapy in the management of resected non-small-cell lung carcinoma: 10 years' experience in a single institute, Int J Radiat Oncol Biol Phys, 76, pp. 433-439, (2010)

[6]

Auperin A., Le Pechoux C., Rolland E., Et al., Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer, J Clin Oncol, 28, pp. 2181-2190, (2010)

[7]

Wind J., Smit E.J., Senan S., Eerenberg J.P., Residual disease at the bronchial stump after curative resection for lung cancer, Eur J Cardiothorac Surg, 32, pp. 29-34, (2007)

[8]

Ghiribelli C., Voltolini L., Paladini P., Luzzi L., Di Bisceglie M., Gotti G., Treatment and survival after lung resection for non-small cell lung cancer in patients with microscopic residual disease at the bronchial stump, Eur J Cardiothorac Surg, 16, pp. 555-559, (1999)

[9]

Olszyna-Serementa M., Socha J., Wierzchowski M., Kepka L., Patterns of failure after postoperative radiotherapy for incompletely resected (R1) non-small cell lung cancer: Implications for radiation target volume design, Lung Cancer, 80, pp. 179-184, (2013)

[10]

Feliciano J., Feigenberg S., Mehta M., Chemoradiation for definitive, preoperative, or postoperative therapy of locally advanced non-small cell lung cancer, Cancer J, 19, pp. 222-230, (2013)

← 1 →